Heterogeneous nuclear ribonucleoprotein K promotes the progression of lung cancer by inhibiting the p53-dependent signaling pathway.
DNA damage response
hnRNPK
lung cancer
p53
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
28
02
2022
received:
05
01
2022
accepted:
01
03
2022
pubmed:
31
3
2022
medline:
4
5
2022
entrez:
30
3
2022
Statut:
ppublish
Résumé
Heterogeneous nuclear ribonucleoprotein K (hnRNPK) is a nucleic acid-binding protein. Reportedly, hnRNPK is overexpressed in many human tumors, and such overexpression is associated with poor prognosis, implicating the role of hnRNPK as an oncogene during tumorigenesis. In this study, hnRNPK expression in lung cancer tissues was investigated. Briefly, hnRNPK was knocked down in lung cancer cell lines, and effects of knockdown on the cell proliferation, migration, and cell cycle were assessed using a cell counting kit-8 (CCK-8) assay, colony formation assay, transwell assay and flow cytometry. The effects of hnRNPK knockdown on the p53-dependent signaling pathway were examined using western blotting. Finally, the effect of hnRNPK knockdown on tumor growth was verified in vivo using a lung cancer xenograft mouse model. hnRNPK knockdown inhibited the cell proliferation, migration and cell cycle. In addition to phenotypic changes, hnRNPK knockdown upregulated expressions of pCHK1, pCHK2, and p53，p21，cyclin D1, thereby mediating the DNA damage response (DDR). The regulatory function of hnRNPK during p53/p21/cyclin D1 signaling in hnRNPK-knockdown A549 cells was confirmed by suppressed the protein expression of associated signaling pathways, which inhibited DDR. hnRNPK plays a crucial role in the progression of lung cancer, ultimately affecting survival rate. Inhibition of progression of lung cancer cells induced by hnRNPK-knockdown is dependent on activation of p53 by the p53/p21/cyclin D1 pathway.
Sections du résumé
BACKGROUND
Heterogeneous nuclear ribonucleoprotein K (hnRNPK) is a nucleic acid-binding protein. Reportedly, hnRNPK is overexpressed in many human tumors, and such overexpression is associated with poor prognosis, implicating the role of hnRNPK as an oncogene during tumorigenesis. In this study, hnRNPK expression in lung cancer tissues was investigated.
METHODS
Briefly, hnRNPK was knocked down in lung cancer cell lines, and effects of knockdown on the cell proliferation, migration, and cell cycle were assessed using a cell counting kit-8 (CCK-8) assay, colony formation assay, transwell assay and flow cytometry. The effects of hnRNPK knockdown on the p53-dependent signaling pathway were examined using western blotting. Finally, the effect of hnRNPK knockdown on tumor growth was verified in vivo using a lung cancer xenograft mouse model.
RESULTS
hnRNPK knockdown inhibited the cell proliferation, migration and cell cycle. In addition to phenotypic changes, hnRNPK knockdown upregulated expressions of pCHK1, pCHK2, and p53，p21，cyclin D1, thereby mediating the DNA damage response (DDR). The regulatory function of hnRNPK during p53/p21/cyclin D1 signaling in hnRNPK-knockdown A549 cells was confirmed by suppressed the protein expression of associated signaling pathways, which inhibited DDR.
CONCLUSION
hnRNPK plays a crucial role in the progression of lung cancer, ultimately affecting survival rate. Inhibition of progression of lung cancer cells induced by hnRNPK-knockdown is dependent on activation of p53 by the p53/p21/cyclin D1 pathway.
Identifiants
pubmed: 35352475
doi: 10.1111/1759-7714.14387
pmc: PMC9058298
doi:
Substances chimiques
Heterogeneous-Nuclear Ribonucleoprotein K
0
Tumor Suppressor Protein p53
0
Cyclin D1
136601-57-5
HNRNPK protein, human
146410-60-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1311-1321Informations de copyright
© 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Curr Biol. 2000 Jul 27-Aug 10;10(15):886-95
pubmed: 10959836
Cell. 2005 Jan 14;120(1):7-10
pubmed: 15652475
J Biol Chem. 2012 Aug 31;287(36):30789-99
pubmed: 22825850
Mol Cell Biol. 2004 Mar;24(5):2052-62
pubmed: 14966284
Oral Oncol. 2012 Jun;48(6):516-22
pubmed: 22321252
Nucleic Acids Res. 1993 Mar 11;21(5):1193-8
pubmed: 8464704
Radiat Oncol. 2016 Sep 06;11(1):115
pubmed: 27600665
Int J Cancer. 2012 Aug 1;131(3):582-90
pubmed: 22015967
Zhongguo Fei Ai Za Zhi. 2008 Apr 20;11(2):241-5
pubmed: 20731909
J Biol Chem. 2001 Mar 30;276(13):9699-704
pubmed: 11121407
J Biol Chem. 1993 Aug 25;268(24):18249-58
pubmed: 8349701
Ann Surg Oncol. 2010 Oct;17(10):2619-27
pubmed: 20499280
FEBS Lett. 1997 Feb 17;403(2):113-5
pubmed: 9042948
J Biol Chem. 2013 May 24;288(21):15046-56
pubmed: 23564449
Thorac Cancer. 2022 May;13(9):1311-1321
pubmed: 35352475
JAMA. 2019 Aug 27;322(8):764-774
pubmed: 31454018
Oncotarget. 2017 Oct 17;8(61):103364-103374
pubmed: 29262567
Mol Cell Biol. 2003 Dec;23(23):8405-15
pubmed: 14612387
Mol Cell Biol. 2002 Jul;22(13):4535-43
pubmed: 12052863
Oncogene. 2004 Mar 4;23(9):1693-703
pubmed: 14647428
Mol Cancer Ther. 2009 Oct;8(10):2882-93
pubmed: 19825806
N Engl J Med. 2013 May 30;368(22):2059-74
pubmed: 23634996
Mol Cell Biol. 2001 Jul;21(13):4129-39
pubmed: 11390642
Animal Model Exp Med. 2019 Nov 21;2(4):291-296
pubmed: 31942561
Curr Opin Cell Biol. 2002 Apr;14(2):237-45
pubmed: 11891124
Cancer Lett. 2014 Oct 1;352(2):152-9
pubmed: 25016060
Nat Rev Mol Cell Biol. 2013 Aug;14(8):518-28
pubmed: 23877564
Mol Cell Biol. 2005 Aug;25(15):6436-53
pubmed: 16024782
Nature. 1997 May 15;387(6630):296-9
pubmed: 9153395
Oncol Lett. 2020 Dec;20(6):394
pubmed: 33193854
Int J Mol Sci. 2020 May 08;21(9):
pubmed: 32397297
Annu Rev Biochem. 2004;73:39-85
pubmed: 15189136
J Biol Chem. 1998 Mar 6;273(10):5858-68
pubmed: 9488723